Sage Journals: Discover world-class research

Abstract

CBP/p300 interacting transactivator with Glu/Asp-rich carboxy-terminal domain 1 (CITED1) is a transcriptional activator belonging to the non-DNA-binding transcription co-regulator family. It regulates diverse pathways, including the transforming growth factor/bone morphogenetic protein/SMAD, estrogen, Wnt-β-catenin, and androgen-AR signaling pathways, by binding to CBP/p300 co-activators through its conserved transactivation domain CR2. CITED1 plays an important role in embryonic development and a certain regulatory role in the occurrence and development of various tumors. In this article, the biological characteristics, expression regulation, participating signaling pathways, and potential roles of CITED1 in the clinical diagnosis and treatment of tumors are reviewed.

Keywords

CBP/p300 interacting transactivator with Glu/Asp-rich carboxy-terminal domain 1 (CITED1)tumor transcription diagnosis treatment prognosis transactivation

Introduction

CBP/p300 interacting transactivator with Glu/Asp-rich carboxy-terminal domain 1 (CITED1) was originally named melanocyte-specific gene 1 (MSG1) because it was believed to be expressed only in melanocytes.¹ Subsequently, the extra-melanocytic expression of MSG1 in mammary epithelium, testes, the brain, embryonic tissues, and some tumors was detected, and its biological characteristics were elucidated.^1–5 Therefore, “MSG1” was renamed “CITED1.”

Biological characteristics of CITED1

The CITED1 gene, located on chromosome Xq13.1, is highly conserved with three exons and two introns, and its 5ʹ end contains a TATA box and potential binding sites for multiple transcription factors (USF, Brn-3, Brn-2, TFE3, Oct-1, AP-2, and Sp1).⁶ The promoter fragment activates transcription of the CITED1 gene, which encodes a 27-kDa nuclear protein. CITED1 shares a highly conserved transcriptional activation region (CR2) with other members of the CITED family, including CITED2 (MRG1 or p35srj), CITED3, and CITED4.^7,8 CR2 (amino acids 145–193), a C-terminal acidic domain containing six aspartic acid and six glutamic acid residues, enhances the transcriptional activation activity of CITED1 by binding to the co-activators CBP/p300.^1,7 Heat shock cognate protein 70, hypoxia-inducible factor-1, β-catenin, and microphthalmia-associated transcription factor (MITF) compete with CITED1 for binding to CBP/p300, thereby repressing related transcription.^8–11 Moreover, phosphorylation of five serine residues of CITED1 in M-phase (Ser16, Ser63, Ser67, Ser71, and Ser137) also interferes with the binding of CITED1 to CBP/p300, thus reducing the ability of CITED1 to activate transcription.¹²

Because CITED1 lacks DNA-binding activity, it serves as a mediator to stabilize and augment the interaction between CBP/p300 and certain DNA-binding proteins, and then they translocate to the nucleus as complexes, where they bind to the promoters of target genes and enhance corresponding transcription. Among these binding partners, CITED1 binds to the transcription factor SMAD4 through its N-terminal SMAD4-interacting domain (amino acids 30–60), enhancing transforming growth factor β (TGF-β)/bone morphogenetic protein (BMP)-induced transcription depending on SMAD hetero-oligomerization.^8,13,14 CITED1 binds to estrogen receptor α (ERα) through its N-terminal CR2 region (amino acids 157–158), and this binding is independent of the interaction region with CBP/p300, permitting the coactivation of estrogen-dependent transcription (Figure 1). ¹⁵ CITED1 additionally binds to TOX high mobility group box family member 3 (TOX3) through CR2, thereby significantly enhancing estrogen response element-dependent transcription and playing an anti-apoptotic role.¹⁶ The subcellular localization of CITED1 is characterized by cellular heterogeneity. In HEK and MCF-7 cells, the centralized distribution of CITED1 in the cytoplasm was confirmed to be associated with chromosomal region maintenance 1 (CRM1)-dependent nuclear export signals (¹⁰⁸LMSLVVELGL¹¹⁷) on CR2, whereas in osteoblasts, the parathyroid hormone-induced nuclear translocation of CITED1 was confirmed to be associated with phosphorylation at Ser79 and activation of protein kinase C (PKC).^12,17

Figure 1.

The biological characteristics of CITED1. (1) CR2 enhances the transcriptional activity of CITED1 by binding to the co-activators CBP/p300. (2) Because CITED1 lacks DNA-binding activity, it serves as a mediator to stabilize and augment the interaction between CBP/p300 and some DNA-binding proteins. CITED1, CBP/p300 interacting transactivator with Glu/Asp-rich carboxy-terminal domain 1.

CITED1 is involved in the process of embryonic development, including the development of the metanephric mesenchyme, ureter, placenta, and brain.^4,5,14 The loss of CITED1 often leads to abnormal embryonic development.¹⁸ In addition, CITED1 plays a certain regulatory role in the occurrence and development of various tumors. To provide a valuable theoretical basis for further study of CITED1, this article reviews the research progress on CITED1 in these tumors and its potential function in clinical tumor diagnosis and treatment.

Expression regulation of CITED1

Currently, there are few studies on the regulatory mechanism of CITED1 expression. Existing studies suggest that certain regulatory factors can regulate the expression of CITED1 at the transcriptional or post-transcriptional level. In melanocytes and melanoma, the PKC activators 12-O-tetradecanoyl phorbol-13-acetate/endothelin-1 (ET-1) and receptor tyrosine kinase activator fibroblast growth factor-2 (FGF-2) regulate the expression of CITED1 at the transcriptional and post-transcriptional levels, respectively.¹⁹ Studies suggest that under UV-B irradiation, epidermal keratinocytes can secrete ET-1 and FGF-2, which act on melanocytes in a paracrine manner, leading to increased CITED1 expression.¹⁹

BRAF activating mutations are also involved in the regulation of CITED1 expression, but they play different roles in different tumor types. BRAF activating mutations are common in melanoma and papillary thyroid carcinoma (PTC). Studies revealed that in melanoma, BRAF activating mutations downregulate CITED1 expression by enhancing the expression and function of the transcription factor nuclear receptor subfamily 4 group A member 1/2.¹⁰ However, in PTC, the BRAF V600E mutation induces high expression of CITED1 mRNA via hypomethylation of CpGs in the CITED1 promoter (especially CpG18 and CpG24).²⁰

In addition, miR-26, the Runx1/CBFβ complex, and c-Myc were found to be involved in the regulation of CITED1 expression in tumors, but the specific regulatory mechanisms remain to be further explored.^21–23

The main signaling pathways and role of CITED1 in tumors

TGF-β/BMP/SMAD signaling pathway

TGF-β plays a dual role in tumorigenesis and development. When tumor cells successfully evade the growth-inhibiting effect of TGF-β, TGF-β–mediated oncogenic functions, such as the induction of epithelial-to-mesenchymal transition (EMT), can be used to promote tumor cell survival, proliferation, invasion, and metastasis. In the process of tumor cell growth and metastasis, various cells in the tumor microenvironment often release a large amount of TGF-β, which directly promotes the malignant transformation of tumor cells. Studies illustrated that CITED1 is highly expressed in the invasive front of melanoma. CITED1 enhances the transcription of the TGF-β/SMAD signaling pathway-related target genes JAK1, leukemia inhibitory factor, interleukin 11 (IL11), myosin phosphatase rho interacting protein, and rho guanine nucleotide exchange factor 5; promotes cooperation between Rho/ROCK and JAK1/STAT3 signaling; and provides the high levels of actomyosin contractility for melanoma cells to migrate in the rounded ‘‘amoeboid’’ mode (Figure 2).^24,25 In colorectal cancer (CRC), CITED1, through an association with TGF-β/SMAD signaling, was found to be one of the genes leading to the dedifferentiation of CRC invasive front cells, and the metastatic ability of CRC invasive front cells without the epithelial phenotype was enhanced.²⁶ In addition, CITED1 overexpression induces the differentiation of embryonic stem cells into trophoblast cells by activating the BMP signaling pathway, leading to teratoma formation (Figure 3).²⁷

Figure 2.

CITED1 promotes amoeboid melanoma migration. CITED1 enhances the transcription of TGF-β/SMAD signaling pathway target genes (JAK1, LIF, IL11, M-RIP, and ARHGEF5), promotes the cooperation between Rho/ROCK and JAK1/STAT3 signaling, and provides high levels of actomyosin contractility for melanoma cells to migrate in the rounded ‘‘amoeboid’’ mode. CITED1, CBP/p300 interacting transactivator with Glu/Asp-rich carboxy-terminal domain 1; LIF, leukemia inhibitory factor; IL11, interleukin 11; M-RIP, myosin phosphatase rho interacting protein; ARHGEF5, rho guanine nucleotide exchange factor 5.

Figure 3.

CITED1 induces teratoma formation. CITED1 overexpression induces the differentiation of ESCs into trophoblast cells by activating BMP signaling pathway, leading to the formation of teratoma. CITED1, CBP/p300 interacting transactivator with Glu/Asp-rich carboxy-terminal domain 1; ESCs, embryonic stem cells; BMP, bone morphogenetic protein.

Estrogen signaling pathway

CITED1 activates the transcription of amphiregulin (AREG) via the estrogen signaling pathway during adolescent breast development, thus promoting the growth of mammary epithelium and the formation of mammary ducts.^2,28 In addition, AREG has been identified as a downstream effector of estrogen in ER+ breast cancer, and its expression is necessary for the growth of MCF-7 xenografts.²⁹ CITED1 can also coactivate the estrogen-dependent ER-mediated transcription of TGF-α, promoting the growth of MCF-7 cells in an autocrine manner. The effect is more apparent when the estrogen concentration is low because CITED1 enhances the sensitivity of MCF-7 cells to estrogen.¹⁵ However, the latest literature confirms that MCF-7 cells overexpressing CITED1 exhibit selective amplification of AREG but not TGF-α, and the maintenance of specific ERα/CITED1-mediated transcription is a good prognostic marker in patients with anti-endocrine–treated ER+/LN- breast cancer.^28,30 Therefore, the role of CITED1 in regulating TGF-α transcription in MCF-7 cells remains controversial and further exploration is needed. In addition, the EGR2/CITED1 transcription factor complex can bind to the ErbB2 promoter and increase the expression of human epithelial growth factor receptor 2 (HER2).³¹ HER2 overexpression is related to the occurrence of breast cancer and poor prognosis. Therefore, the mechanism and clinical role of CITED1 might depend on the molecular subtype of breast cancer (Figure 4).

Figure 4.

The role of CITED1 in breast cancer. (1) CITED1 can selectively coactivate the estrogen-dependent ER-mediated transcription of AREG and TGF-α. (2) The EGR2/CITED1 transcription factor complex can bind to the ErbB2 promoter and enhance the expression of HER2. CITED1, CBP/p300 interacting transactivator with Glu/Asp-rich carboxy-terminal domain 1; ER, estrogen receptor, AREG, amphiregulin; TGF-α, transforming growth factor α.

Wnt/β-catenin signaling pathway

The Wnt/β-catenin signaling pathway is involved in maintaining the balance between proliferation and differentiation in a variety of tumors, and this role is related to the transcription coactivator CBP/p300.^32–34 Specifically, the binding of CBP to β-catenin activates transcription of cell proliferation-related genes, whereas the binding of p300 to β-catenin mediates transcription of cell differentiation-related genes.³⁵ CBP/P300 is the main protein interacting with CITED1. Thus, CITED1 might act as a coregulator controlling the balance between CBP/β-catenin–mediated transcription (maintaining stem/progenitor cell proliferation) and p300/β-catenin-mediated transcription (initiating cell differentiation).

During vertebrate development, CITED1 is highly expressed in the progenitor cells of embryonic tissues, but its expression is downregulated and ultimately lost when they differentiate into mature tissues. Because of the persistent presence of undifferentiated components, embryonic tumors usually have high CITED1 expression.³⁶ CITED1 is expressed in both the cytoplasm and nucleus of Wilms tumor (WT) blastemal cells. CITED1 in the cytoplasm confers stemness to cancer cells by inhibiting the Wnt-β/catenin signaling pathway, whereas CITED1 in the nucleus is more tumorigenic.^37,38 In hepatoblastoma, CITED1 induces cell proliferation by upregulating the Wnt signaling pathway inhibitors kringle-containing transmembrane protein 1 and CXXC finger protein 4.³⁹

CITED1 is highly expressed in adenomatous polyposis coli (APC)-deficient CRC mouse models and human tissue samples, and knockdown of CITED1 extended the lifespan of APC-deficient CRC mice. As a member of the β-catenin degradation complex, APC negatively regulates β-catenin. Loss of APC can induce activation of the Wnt-β/catenin signaling pathway and enhance c-Myc-dependent CITED1 transcription, whereas negative feedback of upregulation of CITED1 expression inhibits hyperactivation of the Wnt signaling pathway and maintains the activity of the Wnt signaling pathway at the level promoting tumor development (Figure 5).²³ In addition, CITED1 also promotes tumor cell proliferation by inhibiting the Wnt/β-catenin signaling pathway in PTC.⁴⁰

Figure 5.

The mechanism of CITED1 in APC-deficient CRC. Loss of APC can induce activation of the Wnt-β/catenin signaling pathway and enhance c-Myc-dependent CITED1 transcription, whereas negative feedback via CITED1 upregulation inhibits hyperactivation of the Wnt signaling pathway and maintains the activity of this pathway at the level promoting tumor development. CITED1, CBP/p300 interacting transactivator with Glu/Asp-rich carboxy-terminal domain 1; APC, adenomatous polyposis coli; CRC, colorectal cancer.

Androgen/androgen receptor (AR) signaling pathway

The androgen/AR signaling pathway plays an important role in all stages of prostate cancer occurrence and development. CITED1 enhances the transcriptional activity of AR.¹⁵ Prior research found that CITED1 expression is not increased in human prostate cancer tissue samples, but it is highly expressed in PIN-like tissue samples (a precursor to prostate cancer) of mice carrying the AR E231G mutation. Knockdown of CITED1 can reduce the viability and proliferation of LNCaP prostate cancer cells.⁴¹ Thus, it is speculated that CITED1 plays a role in promoting the survival of premalignant cells during prostate cancer initiation, but its sustained overexpression is not necessary for tumor progression.

Potential role of CITED1 in clinical tumor diagnosis and treatment

CITED1 expression is higher in melanoma, PTC, WT, and CRC than in normal tissues, and its expression is closely related to tumor stage, metastasis, and prognosis.

In melanoma, high CITED1 expression is considered a biomarker distinguishing melanoma from benign nevus.⁴² The BRAF V600E mutational load is negatively correlated with melanoma progression.⁴³ Therefore, a low mutational load of BRAF V600E (<5%) combined with the synergistic high expression of CITED1 can be used as an indicator of poor prognosis of melanoma. CITED1 has also been proven to negatively regulate MITF, specifically repressing MITF to maintain its level in a range compatible with tumorigenesis, suggesting that CITED1 can be a therapeutic target for genetic manipulation. Successful implementation of such a strategy would result in the cell-specific enhancement of MITF expression and potentially induce cyclin-dependent kinase inhibitor 1A (CDKN1A)/p21 and CDKN1C/p57-dependent cell growth arrest, thereby increasing the sensitivity of melanoma to chemotherapy.¹¹

In PTC, previous studies confirmed that Hector Battifora mesothelial antigen-1 (HBME-1) is the most sensitive (92.8%) and specific (86.4%) marker distinguishing PTC from benign thyroid nodules, and negative staining for cytokeratin 19 (CK19) is helpful in excluding PTC. As CITED1 is preferentially expressed in PTC but not in follicular carcinoma and normal thyroid tissue, it is recommended to combine CITED1 with HBME-1 and CK19 to attain high sensitivity and specificity for differential diagnosis.^44–48 In addition, high CITED1 expression is associated with clinical stage (P = 0.003) and lymph node metastasis (P = 0.006) in PTC.⁴⁹ Studies revealed that CITED1 promotes the proliferation of PTC cells via the regulation of p21 and p27,⁵⁰ and CITED1 silencing might inhibit the progression of PTC cells by inhibiting the PI3K/AKT pathway.⁵¹ All of these findings indicate that CITED1 can be used as an indicator of diagnosis and prognosis in PTC, and it might be a potential therapeutic target in the treatment of PTC.

The level of CITED1 in WT blastema is positively correlated with tumor stage, and it is expected to be a prognostic indicator of WT.³⁶ CITED1, as a marker of nephrogenic progenitor cells with cancer stem cell characteristics in WT, might represent a target for novel therapy that inhibits cell proliferation and promotes terminal differentiation.^36,38,52 Other scholars proposed that dual immunofluorescence staining of CITED1 and epithelial cell markers (such as cytokeratin) can improve the recognition ability of blastemal WT in histologically high-risk groups and thus guide treatment.⁵³

In the diagnosis and treatment of CRC, the detection rate of early CRC has increased greatly with the improvement of endoscopic equipment and techniques, and the presence of lymph node metastasis has become a major concern to determine the treatment strategy. In T₁ CRC, high CITED1 expression is an independent risk factor for lymph node metastasis (P = 0.010).⁵⁴ Therefore, CITED1 can be used as a potential marker to predict CRC metastasis and prognosis and to guide treatment.

Of course, the mechanism of CITED1 in the aforementioned tumors remains unknown, and further research is needed. Meanwhile, additional research is also needed to determine whether CITED1 plays a role in other tumors and whether it has potential diagnostic and therapeutic functions. For example, high-throughput sequencing of a cancer-associated fibroblast-induced EMT model of lung cancer cells revealed that CITED1 was upregulated in the early EMT stage of A549 cells (3–24 hours).⁵⁵ In addition, Kaplan–Meier plotter database analysis demonstrated that CITED1 expression was negatively correlated with progression-free survival (hazard ratio [HR] = 1.54, P < 0.001) and overall survival (HR = 1.17, P = 0.024) in lung cancer. We believe that with increasing research on CITED1, its tumor-promoting effect will be clarified.

Association of CITED1 with beige fat

Beige fat is produced by white fat in response to certain inducible factors through a process called fat/adipose tissue “browning” or “beiging.”^56,57 Similarly as brown fat, beige fat is a thermogenic adipose tissue. However, unlike brown fat, which degrades and disappears with age, beige fat persists in the dorsal spine region of the neck, above the clavicle, and around the aorta in adults, and it can be metabolized to produce heat after stimulation such as cold stimulation, conferring therapeutic effects on obesity and type 2 diabetes.⁵⁸ As a newfound marker of beige fat, the focus of recent research on CITED1 has shifted to the regulation of beige fat formation, obesity, and type 2 diabetes. Cyanidin-3-glucoside, IL4, and peroxisome proliferator-activated receptor γ upregulate CITED1 expression to induce beige fat formation.^59–61 Chronic inflammation promotes tumor development and progression, such as that induced by Helicobacter pylori infection in gastric cancer and human papillomavirus infection in cervical cancer.⁶² Studies indicated that prolonged exposure of adipose tissue macrophages to interferon-γ can increase the expression of interferon-stimulated genes such as CITED1, resulting in adipose tissue “browning” and enhanced pro-inflammatory activity.^63,64 However, it has not been confirmed whether excess lactate released during adjacent adipose tissue “browning” can promote tumor progression.⁶⁵ It is believed that with further research, the relationships of CITED1 with tumor development and progression through beige fat will be elucidated.

Conclusion and prospects

CITED1, as a transcriptional activator, performs transcriptional regulation through multiple signaling pathways including TGF-β/BMP/SMAD, estrogen, Wnt-β/catenin, and androgen/AR. Studies on CITED1 in tumors to date have mainly focused on melanoma, PTC, breast cancer, WT, and CRC. CITED1 plays important roles in tumor proliferation, invasion, and metastasis. Meanwhile, CITED1 is expected to become a potential target for tumor diagnosis and treatment in the future. First, in terms of diagnosis, CITED1 can be used as a diagnostic marker for solid tumors. Through immunohistochemical staining of histopathological section, CITED1 can be used in combination with other markers such as BRAF V600E, and HBME-1 to improve the specificity and sensitivity of tumor diagnosis. Second, as a marker of early tumor metastasis, we can predict potential metastases that have not yet been uncovered by imaging by detecting CITED1 expression in ctDNA and exosomes. Finally, as a marker of advanced tumor metastasis, the severity of metastasis can be assessed by detecting CITED1 levels in metastases and peripheral blood. In terms of treatment, CITED1 can play an anti-tumor role as a therapeutic target. CITED1 is a mediator in multiple signaling pathways, and it is expected to become a new target after drug resistance in upstream and downstream targets. CITED1 is also closely related to tumor metastasis, and this could permit new strategies for targeted therapy for tumor metastasis. In terms of prognosis assessment, the relationship between CITED1 expression and patient survival can be explored through the follow-up of patients in different tumor stages, and we believe that there will be unexpected results.

Footnotes

Author contributions

Wenting Chen, Jianing Jiang, and Jinqi Gao contributed equally to this work. All authors read and approved the final version of the manuscript.

Declaration of conflicting interests

The authors declare that there is no conflict of interest.

Funding

This work was supported by grants from the National Natural Science Foundation of China (#81803109), the Doctor Study-up Foundation of Liaoning Province (2019-BS-010), the High-level Talent Innovation Support Plan of Dalian (2021RQ018), and the Research Project of Dalian Medical Science (2211033).

ORCID iD

Jianing Jiang

References

Shioda

Fenner

Isselbacher

: msg1, a novel melanocyte-specific gene, encodes a nuclear protein and is associated with pigmentation. Proc Natl Acad Sci U S A 1996; 93: 12298–12303.

Howlin

McBryan

Napoletano

, et al. CITED1 homozygous null mice display aberrant pubertal mammary ductal morphogenesis. Oncogene 2006; 25: 1532–1542.

Del Valle

Buonocore

Duncan

, et al. A genomic atlas of human adrenal and gonad development. Wellcome Open Res 2017; 2: 25.

Gerstner

Landry

CF.

Expression of the transcriptional coactivator CITED1 in the adult and developing murine brain. Dev Neurosci 2007; 29: 203–212.

Rodriguez

Sparrow

Scott

, et al. Cited1 is required in trophoblasts for placental development and for embryo growth and survival. Mol Cell Biol 2004; 24: 228–244.

Fenner

Parrish

Boyd

, et al. MSG1 (melanocyte-specific gene 1): mapping to chromosome Xq13.1, genomic organization, and promoter analysis. Genomics 1998; 51: 401–407.

Fernandes

Calado

Mendes-Silva

, et al. CITED2 and the modulation of the hypoxic response in cancer. World J Clin Oncol 2020; 11: 260–274.

Yahata

de Caestecker

Lechleider

, et al. The MSG1 non-DNA-binding transactivator binds to the p300/CBP coactivators, enhancing their functional link to the Smad transcription factors. J Biol Chem 2000; 275: 8825–8834.

Kwong

, et al. Transcriptional regulation and functional implication of the grass carp CITED1 (gcCITED1) in the negative regulation of HIF-1. Int J Biochem Cell Biol 2010; 42: 1544–1552.

10.

Smith

Lim

Pearen

, et al. Regulation of NR4A nuclear receptor expression by oncogenic BRAF in melanoma cells. Pigment Cell Melanoma Res 2011; 24: 551–563.

11.

Howlin

Cirenajwis

Lettiero

, et al. Loss of CITED1, an MITF regulator, drives a phenotype switch in vitro and can predict clinical outcome in primary melanoma tumours. PeerJ 2015; 3: e788.

12.

Shi

Boyle

Sparrow

, et al. The transcriptional activity of CITED1 is regulated by phosphorylation in a cell cycle-dependent manner. J Biol Chem 2006; 281: 27426–27435.

13.

Shioda

Lechleider

Dunwoodie

, et al. Transcriptional activating activity of Smad4: roles of SMAD hetero-oligomerization and enhancement by an associating transactivator. Proc Natl Acad Sci U S A 1998; 95: 9785–9790.

14.

Brown

Muthukrishnan

Guay

, et al. Role for compartmentalization in nephron progenitor differentiation. Proc Natl Acad Sci U S A 2013; 110: 4640–4645.

15.

Yahata

Shao

Endoh

, et al. Selective coactivation of estrogen-dependent transcription by CITED1 CBP/p300-binding protein. Genes Dev 2001; 15: 2598–2612.

16.

Dittmer

Kovacs

Yuan

, et al. TOX3 is a neuronal survival factor that induces transcription depending on the presence of CITED1 or phosphorylated CREB in the transcriptionally active complex. J Cell Sci 2011; 124(Pt 2): 252–260.

17.

Lin

Feng

, et al. Nuclear translocation of CBP/p300-interacting protein CITED1 induced by parathyroid hormone requires serine phosphorylation at position 79 in its 63–84 domain. Cell Signal 2014; 26: 2436–2445.

18.

Novitskaya

Baserga

de Caestecker

MP.

Organ-specific defects in insulin-like growth factor and insulin receptor signaling in late gestational asymmetric intrauterine growth restriction in Cited1 mutant mice. Endocrinology 2011; 152: 2503–2516.

19.

Ahmed

Fenner

, et al. Regulation of expression of MSG1 melanocyte-specific nuclear protein in human melanocytes and melanoma cells. Exp Cell Res 1998; 242: 478–486.

20.

Sassa

Hayashi

Watanabe

, et al. Aberrant promoter methylation in overexpression of CITED1 in papillary thyroid cancer. Thyroid 2011; 21: 511–517.

21.

Zhang

YP.

E2F, HSF2, and miR-26 in thyroid carcinoma: bioinformatic analysis of RNA-sequencing data. Genet Mol Res 2016; 15: 15017576.

22.

van Bragt

Xie

, et al. RUNX1, a transcription factor mutated in breast cancer, controls the fate of ER-positive mammary luminal cells. Elife 2014; 3: e03881.

23.

Méniel

Song

Phesse

, et al. Cited1 deficiency suppresses intestinal tumorigenesis. PLoS Genet 2013; 9: e1003638.

24.

Cantelli

Orgaz

Rodriguez-Hernandez

, et al. TGF-β-Induced Transcription Sustains Amoeboid Melanoma Migration and Dissemination. Curr Biol 2015; 25: 2899–2914.

25.

Sanz-Moreno

Gaggioli

Yeo

, et al. ROCK and JAK1 signaling cooperate to control actomyosin contractility in tumor cells and stroma. Cancer Cell 2011; 20: 229–245.

26.

Oku

Shimoji

Takifuji

, et al. Identification of the molecular mechanisms for dedifferentiation at the invasion front of colorectal cancer by a gene expression analysis. Clin Cancer Res 2008; 14: 7215–7222.

27.

Luo

Fang

, et al. Transcription coactivator Cited1 acts as an inducer of trophoblast-like state from mouse embryonic stem cells through the activation of BMP signaling. Cell Death Dis 2018; 9: 924.

28.

McBryan

Howlin

Kenny

, et al. ERalpha-CITED1 co-regulated genes expressed during pubertal mammary gland development: implications for breast cancer prognosis. Oncogene 2007; 26: 6406–6419.

29.

Peterson

Jenkins

Lofgren

, et al. Amphiregulin Is a Critical Downstream Effector of Estrogen Signaling in ERα-Positive Breast Cancer. Cancer Res 2015; 75: 4830–4838.

30.

Dahlgren

Lettiero

Dalal

, et al. CITED1 as a marker of favourable outcome in anti-endocrine treated, estrogen-receptor positive, lymph-node negative breast cancer. BMC Res Notes 2023; 16: 105.

31.

Dillon

Brown

Ling

, et al. An EGR2/CITED1 transcription factor complex and the 14-3-3sigma tumor suppressor are involved in regulating ErbB2 expression in a transgenic-mouse model of human breast cancer. Mol Cell Biol 2007; 27: 8648–8657.

32.

Zhan

Rindtorff

Boutros

Wnt signaling in cancer. Oncogene 2017; 36: 1461–1473.

33.

Anastas

Moon

RT.

WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer 2013; 13: 11–26.

34.

Clevers

Nusse

Wnt/β-catenin signaling and disease. Cell 2012; 149: 1192–1205.

35.

Bordonaro

Lazarova

DL.

Determination of the Role of CBP- and p300-Mediated Wnt Signaling on Colonic Cells. JMIR Res Protoc 2016; 5: e66.

36.

Murphy

Pierce

de Caestecker

, et al. SIX2 and CITED1, markers of nephronic progenitor self-renewal, remain active in primitive elements of Wilms' tumor. J Pediatr Surg 2012; 47: 1239–1249.

37.

Fukuzawa

Anaka

Morison

, et al. The developmental programme for genesis of the entire kidney is recapitulated in Wilms tumour. PLoS One 2017; 12: e0186333.

38.

Murphy

Pierce

de Caestecker

, et al. CITED1 confers stemness to Wilms tumor and enhances tumorigenic responses when enriched in the nucleus. Oncotarget 2014; 5: 386–402.

39.

Murphy

de Caestecker

Pierce

, et al. CITED1 expression in liver development and hepatoblastoma. Neoplasia 2012; 14: 1153–1163.

40.

Wang

Huang

, et al. CITED1 contributes to the progression of papillary thyroid carcinoma via the Wnt/β-catenin signaling pathway. Onco Targets Ther 2019; 12: 6769–6777.

41.

Thompson

Day

Bianco-Miotto

, et al. A gene signature identified using a mouse model of androgen receptor-dependent prostate cancer predicts biochemical relapse in human disease. Int J Cancer 2012; 131: 662–672.

42.

Huang

Sheng

Jia

, et al. Identification of melanoma biomarkers based on network modules by integrating the human signaling network with microarrays. J Cancer Res Ther 2014; 10 Suppl: C114–C124.

43.

Sevilla

Morales

Ezkurra

, et al. BRAF V600E mutational load as a prognosis biomarker in malignant melanoma. PLoS One 2020; 15: e0230136.

44.

Huang

Prasad

Lemon

, et al. Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. Proc Natl Acad Sci U S A 2001; 98: 15044–15049.

45.

Prasad

Pellegata

Kloos

, et al. CITED1 protein expression suggests Papillary Thyroid Carcinoma in high throughput tissue microarray-based study. Thyroid 2004; 14: 169–175.

46.

Nasr

Mukhopadhyay

Zhang

, et al. Immunohistochemical markers in diagnosis of papillary thyroid carcinoma: Utility of HBME1 combined with CK19 immunostaining. Mod Pathol 2006; 19: 1631–1637.

47.

Chuang

Wang

Tsai

, et al. Immunohistochemistry Helps to Distinguish Noninvasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features/Noninvasive Encapsulated Follicular Variant of Papillary Thyroid Carcinoma with Other Follicular Thyroid Lesions. Medicina (Kaunas) 2021; 57: 1246.

48.

Xin

Guan

Meng

, et al. Diagnostic accuracy of CK-19, Galectin-3 and HBME-1 on papillary thyroid carcinoma: a meta-analysis. Int J Clin Exp Pathol 2017; 10: 8130–8140.

49.

Xia

Wang

Bhandari

, et al. CITED1 gene promotes proliferation, migration and invasion in papillary thyroid cancer. Oncol Lett 2018; 16: 105–112.

50.

Guan

Guo

, et al. CITED1 promotes proliferation of papillary thyroid cancer cells via the regulation of p21 and p27. Cell Biosci 2018; 8: 57.

51.

Chen

Xie

, et al. Effect of silencing CITED1 gene to regulate PI3K/AKT pathway on the biological function of PTC cells and its mechanism. Cell Mol Biol (Noisy-le-grand) 2023; 69: 113–117.

52.

Petrosyan

Villani

Aguiari

, et al. Identification and Characterization of the Wilms Tumor Cancer Stem Cell. Adv Sci (Weinh) 2023; 10: e2206787.

53.

Sehic

Ciornei

Gisselsson

Evaluation of CITED1, SIX1, and CD56 protein expression for identification of blastemal elements in Wilms tumor. Am J Clin Pathol 2014; 141: 828–833.

54.

Nasu

Oku

Takifuji

, et al. Predicting lymph node metastasis in early colorectal cancer using the CITED1 expression. J Surg Res 2013; 185: 136–142.

55.

Song

Wang

, et al. Epithelial-mesenchymal transition markers screened in a cell-based model and validated in lung adenocarcinoma. BMC Cancer 2019; 19: 680.

56.

Boström

Sparks

, et al. Beige adipocytes are a distinct type of thermogenic fat cell in mouse and human. Cell 2012; 150: 366–376.

57.

Cohen

Spiegelman

BM.

Adaptive thermogenesis in adipocytes: is beige the new brown?

Genes Dev 2013; 27: 234–250.

58.

Cohen

Spiegelman

BM.

Brown and Beige Fat: Molecular Parts of a Thermogenic Machine. Diabetes 2015; 64: 2346–2351.

59.

Matsukawa

Villareal

Motojima

, et al. Increasing cAMP levels of preadipocytes by cyanidin-3-glucoside treatment induces the formation of beige phenotypes in 3T3-L1 adipocytes. J Nutr Biochem 2017; 40: 77–85.

60.

Lizcano

Vargas

Gómez

, et al. Human ADMC-Derived Adipocyte Thermogenic Capacity Is Regulated by IL-4 Receptor. Stem Cells Int 2017; 2017: 2767916.

61.

Vargas

Rosales

Lizcano

Modifications of Human Subcutaneous ADMSC after PPARγ Activation and Cold Exposition. Stem Cells Int 2015; 2015: 196348.

62.

Zhao

Yan

, et al. Inflammation and tumor progression: signaling pathways and targeted intervention. Signal Transduct Target Ther 2021; 6: 263.

63.

Subramani

Hite

MEL

Garcia

, et al. Regulation of macrophage IFNγ-stimulated gene expression by the transcriptional coregulator CITED1. J Cell Sci 2023; 136: jcs260529.

64.

Wang

Tang

, et al. Slit3 secreted from M2-like macrophages increases sympathetic activity and thermogenesis in adipose tissue. Nat Metab 2021; 3: 1536–1551.

65.

Wei

Sun

Dong

, et al. The thermogenic activity of adjacent adipocytes fuels the progression of ccRCC and compromises anti-tumor therapeutic efficacy. Cell Metab 2021; 33: 2021–2039.e8.

Roles and signaling pathways of CITED1 in tumors: overview and novel insights

Abstract

Keywords

Introduction

Biological characteristics of CITED1

Expression regulation of CITED1

The main signaling pathways and role of CITED1 in tumors

TGF-β/BMP/SMAD signaling pathway

Estrogen signaling pathway

Wnt/β-catenin signaling pathway

Androgen/androgen receptor (AR) signaling pathway

Potential role of CITED1 in clinical tumor diagnosis and treatment

Association of CITED1 with beige fat

Conclusion and prospects

Footnotes

Author contributions

Declaration of conflicting interests

Funding

ORCID iD

References